Tiziana Life Sciences PLC Company Profile (LON:TILS)

About Tiziana Life Sciences PLC (LON:TILS)

Tiziana Life Sciences PLC logoTiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: £141 million
  • Outstanding Shares: 94,393,000
Average Prices:
  • 50 Day Moving Avg: GBX 151.80
  • 200 Day Moving Avg: GBX 176.23
  • 52 Week Range: GBX 102.06 - GBX 240
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.04 per share
  • Price / Book: 42.68
Profitability:
  • EBITDA: ($7,280,000.00)
  • Return on Equity: -188.71%
  • Return on Assets: -151.53%
Misc:
  • Average Volume: 5,036 shs.
 

Frequently Asked Questions for Tiziana Life Sciences PLC (LON:TILS)

What is Tiziana Life Sciences PLC's stock symbol?

Tiziana Life Sciences PLC trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How were Tiziana Life Sciences PLC's earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) released its quarterly earnings results on Friday, September, 29th. The company reported ($4.10) EPS for the quarter, missing the consensus estimate of ($2.00) by $2.10. View Tiziana Life Sciences PLC's Earnings History.

Where is Tiziana Life Sciences PLC's stock going? Where will Tiziana Life Sciences PLC's stock price be in 2017?

1 brokers have issued 1 year price targets for Tiziana Life Sciences PLC's shares. Their forecasts range from GBX 400 to GBX 400. On average, they anticipate Tiziana Life Sciences PLC's stock price to reach GBX 400 in the next twelve months. View Analyst Ratings for Tiziana Life Sciences PLC.

Who are some of Tiziana Life Sciences PLC's key competitors?

Who are Tiziana Life Sciences PLC's key executives?

Tiziana Life Sciences PLC's management team includes the folowing people:

  • Gabriele M. Cerrone, Executive Chairman of the Board
  • Kunwar Shailubhai Ph.D., Chief Executive Officer, Chief Scientific Officer, Director
  • Tiziano Lazzaretti, Chief Financial Officer
  • James Tripp, Chief Operating Officer, Head of Global Clinical Operations
  • P. Cooper, Company Secretary
  • Percy W. C. Lomax, Non-Executive Director
  • Willy Jules Simon, Non-Executive Director

How do I buy Tiziana Life Sciences PLC stock?

Shares of Tiziana Life Sciences PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tiziana Life Sciences PLC's stock price today?

One share of Tiziana Life Sciences PLC stock can currently be purchased for approximately GBX 149.38.


MarketBeat Community Rating for Tiziana Life Sciences PLC (LON TILS)
Community Ranking:  1.3 out of 5 (star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  138
MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tiziana Life Sciences PLC (LON:TILS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: GBX 400
Consensus Price Target History for Tiziana Life Sciences PLC (LON:TILS)
Price Target History for Tiziana Life Sciences PLC (LON:TILS)
Analysts' Ratings History for Tiziana Life Sciences PLC (LON:TILS)
Show:
DateFirmActionRatingPrice TargetDetails
10/2/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 400View Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Tiziana Life Sciences PLC (LON:TILS)
Earnings by Quarter for Tiziana Life Sciences PLC (LON:TILS)
Earnings History by Quarter for Tiziana Life Sciences PLC (LON TILS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/29/2017S1 2017GBX (2)GBX (4.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tiziana Life Sciences PLC (LON:TILS)
Current Year EPS Consensus Estimate: $-1.700 EPS

Dividends

Dividend History for Tiziana Life Sciences PLC (LON:TILS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tiziana Life Sciences PLC (LON:TILS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Tiziana Life Sciences PLC (LON:TILS)
Latest Headlines for Tiziana Life Sciences PLC (LON:TILS)
Source:
DateHeadline
finance.yahoo.com logoHow Does Investing In Tiziana Life Sciences PLC (AIM:TILS) Impact Your Portfolio?
finance.yahoo.com - October 3 at 1:35 PM
lse.co.uk logoMotif Bio Share Chat
www.lse.co.uk - October 1 at 7:08 PM
fool.co.uk logo2 small-cap growth stocks that could make you a millionaire
www.fool.co.uk - September 30 at 7:33 PM
morningstar.co.uk logoTiziana Life Sciences Interim Loss Widens In "Busy" First Half
www.morningstar.co.uk - September 29 at 10:07 AM
americanbankingnews.com logoTiziana Life Sciences PLC (TILS) Releases Quarterly Earnings Results, Misses Estimates By $2.10 EPS
www.americanbankingnews.com - September 29 at 8:20 AM
americanbankingnews.com logoTiziana Life Sciences PLC (TILS) Receives Speculative Buy Rating from Beaufort Securities
www.americanbankingnews.com - September 10 at 12:44 PM
lse.co.uk logoA Proprietary Oral Formulation of Foralumab - London South East (registration) (blog)
www.lse.co.uk - September 7 at 9:58 AM
morningstar.co.uk logoTiziana Life Sciences Develops Oral Formulation Of Foralumab
www.morningstar.co.uk - September 6 at 9:10 AM
americanbankingnews.com logoBeaufort Securities Reaffirms Speculative Buy Rating for Tiziana Life Sciences PLC (TILS)
www.americanbankingnews.com - August 20 at 5:02 PM
businesswire.com logoPublication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy ... - Business Wire (press release)
www.businesswire.com - July 30 at 6:43 AM
finance.yahoo.com logoPublication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
finance.yahoo.com - July 28 at 8:48 AM
americanbankingnews.com logoTiziana Life Sciences PLC (LON:TILS) Receives "Speculative Buy" Rating from Beaufort Securities
www.americanbankingnews.com - July 23 at 10:48 AM
finance.yahoo.com logoTiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma
finance.yahoo.com - July 20 at 8:35 AM
lse.co.uk logoProposed changes to CLNs and Warrant Terms - London South East (registration) (blog)
www.lse.co.uk - July 14 at 9:13 AM
lse.co.uk logoBcl-3 pre-clinical update and Director's dealing - London South East (registration) (blog)
www.lse.co.uk - June 10 at 3:24 AM
morningstar.co.uk logoTiziana Life Sciences Stops Funding For Cardiff University Programme (ALLISS)
www.morningstar.co.uk - June 9 at 1:55 AM
bloomberg.com logoBiotech Is Really Interested in 100-Year-Old Italians
www.bloomberg.com - June 2 at 8:26 PM
businesswire.com logoTiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with ... - Business Wire (press release)
www.businesswire.com - April 26 at 3:17 PM
lse.co.uk logoWarrant Expiry - Reminder - London South East (registration) (blog)
www.lse.co.uk - January 18 at 12:30 AM
businesswire.com logoTiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody - Business Wire (press release)
www.businesswire.com - January 4 at 6:44 AM
uk.finance.yahoo.com logoTiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody
uk.finance.yahoo.com - January 3 at 9:18 AM
biz.yahoo.com logoHalf Year 2016 Tiziana Life Sciences PLC Earnings Release - Before Market Open
biz.yahoo.com - September 29 at 10:19 AM
streetinsider.com logoTiziana Life Sciences PLC: Change of Registered Office
www.streetinsider.com - August 18 at 8:01 PM
marketwatch.com logoTiziana Life Sciences PLC Announces Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of Equity
www.marketwatch.com - June 29 at 10:31 AM
biz.yahoo.com logoFull Year 2015 Tiziana Life Sciences PLC Earnings Release - Time Not Supplied
biz.yahoo.com - June 7 at 7:07 AM
uk.finance.yahoo.com logoTiziana reveals possible new anti-cancer molecule
uk.finance.yahoo.com - January 8 at 4:25 AM

Social

Social activity is not available for this stock.

Chart

Tiziana Life Sciences PLC (TILS) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.